Press Releases October 9, 2026 08:30 AM

Braiin Ltd. to Participate in AI Panel at 2026 Maxim Growth Summit

Braiin Limited CEO to discuss AI trends at 2026 Maxim Growth Summit panel

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
BRAI

Braiin Limited announced its CEO, Natraj Balasubramanian, will participate in an AI-focused panel discussion at the 2026 Maxim Growth Summit in New York City. The panel will cover evolving AI applications, industry benefits, infrastructure, and emerging trends. Braiin also plans one-on-one investor meetings during the conference.

Braiin Ltd. to Participate in AI Panel at 2026 Maxim Growth Summit
BRAI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Braiin's CEO will join a panel titled 'The Shifting Landscape of AI' at the 2026 Maxim Growth Summit, highlighting the company's involvement in AI thought leadership.
  • The panel will address how AI is being adopted internally and externally by businesses, including infrastructure needs and emerging strategies.
  • Braiin operates across AI, agritech, customer experience solutions, PropTech, and living infrastructure, indicating a broad impact across multiple sectors.

NEW YORK, NY, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Braiin Limited (NASDAQ:BRAI) ("Braiin" or the "Company"), a global AI platform company delivering automation and predictive analytics across precision agriculture, customer experience and property technology, announces that Braiin Limited Chief Executive Officer Natraj Balasubramanian will participate in a panel discussion at the 2026 Maxim Growth Summit, taking place October 12 – 14, 2026, at the Hard Rock Hotel in New York City.

2026 Maxim Growth Summit
Date: October 13, 2026
Location: Hard Rock Hotel New York
Panel: “The Shifting Landscape of AI”
Time: 1:30 pm – 2:30 pm ET
Investor Meetings: One-on-one meetings will be held during the conference

Mr. Balasubramanian will join the panel discussion, “The Shifting Landscape of AI,” and discuss the evolving AI landscape alongside other industry leaders.

The panel will explore how artificial intelligence is being employed internally and externally by companies, where businesses are seeing the greatest benefits and returns from AI adoption, the infrastructure buildout required to support continued AI growth, and emerging strategies and trends that may shape the sector.

Mr. Balasubramanian will also hold one-on-one meetings with institutional investors during the conference. Investors interested in scheduling a one-on-one meeting should contact their Maxim Group representative or register for the conference here.

About Braiin Limited

Braiin Limited (NASDAQ:BRAI) is a global technology platform operating across AI, agritech, customer experience solutions, PropTech, and living infrastructure. Braiin's ecosystem combines embedded distribution, intelligent automation, and recurring revenue platforms designed to support the lifecycle of the home and connected consumer services.

Investor Relations Contact:

Mike Mason
CORE IR
(212) 655-0924
[email protected]

Public Relations Contact:

Matthew Cossel
Core PR
(212) 655-0924
[email protected]


Risks

  • The shifting and evolving nature of AI could lead to unpredictable market and technological risks affecting Braiin's business model and growth.
  • Dependence on continuous AI infrastructure build-out may lead to capital intensity and operational risks.
  • Competition in AI and related sectors such as agritech and PropTech is intense, potentially impacting Braiin's market position and financial performance.

More from Press Releases

Edible Garden Receives Preliminary Approval to Sell Tax Credits Through New Jersey Economic Development Authority (NJEDA) Program Oct 9, 2026 High Roller Technologies to Present at the 2026 ThinkEquity Conference Oct 9, 2026 SkinHealth Systems Announces Reverse Stock Split Oct 9, 2026 Gentherm Announces Date for 2026 Third Quarter News Release and Conference Call Oct 9, 2026 HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors Oct 9, 2026